Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.
Drug resistance is an important cause of antiretroviral therapy failure in human immunodeficiency virus (HIV)-infected patients. Mutations in the protease render the virus resistant to protease inhibitors (PIs). Gag cleavage sites also mutate, sometimes correlating with resistance mutations in the protease, but their contribution to resistance has not been systematically analyzed. The present study examines mutations in Gag cleavage sites that associate with protease mutations and the impact of these associations on drug susceptibilities. Significant associations were observed between mutations in the nucleocapsid-p1 (NC-p1) and p1-p6 cleavage sites and various PI resistance-associated mutations in the protease. Several patterns were frequently observed, including mutations in the NC-p1 cleavage site in combination with I50L, V82A, and I84V within the protease and mutations within the p1-p6 cleavage site in combination with D30N, I50V, and I84V within the protease. For most patterns, viruses with mutations both in the protease and in either cleavage site were significantly less susceptible to specific PIs than viruses with mutations in the protease alone. Altered PI resistance in HIV-1 was found to be associated with the presence of Gag cleavage site mutations. These studies suggest that associated cleavage site mutations may contribute to PI susceptibility in highly specific ways depending on the particular combinations of mutations and inhibitors. Thus, cleavage site mutations should be considered when assessing the level of PI resistance.
Kolli
Madhavi
M
Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation St., Worcester, MA 01605, USA.
Stawiski
Eric
E
Chappey
Colombe
C
Schiffer
Celia A
CA
D000595:Amino Acid Sequence; D001665:Binding Sites; D024882:Drug Resistance, Viral / Q000502:physiology*; D016333:HIV Protease / Q000235:genetics / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000378:metabolism* / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology* / Q000502:physiology; D006801:Humans; D008958:Models, Molecular; D008969:Molecular Sequence Data; D009154:Mutation; D020815:Polyproteins / Q000235:genetics / Q000378:metabolism; D011487:Protein Conformation; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000737:chemistry / Q000235:genetics / Q000378:metabolism
D017320:HIV Protease Inhibitors; D020815:Polyproteins; D054301:gag Gene Products, Human Immunodeficiency Virus; D016333:HIV Protease
J Virol. 1998 Sep;72(9):7632-7
9696866
J Virol. 1995 Sep;69(9):5228-35
7636964
Eur J Biochem. 2002 Aug;269(16):4114-20
12180988
N Engl J Med. 2001 Feb 15;344(7):472-80
11172188
Eur J Biochem. 1999 Jul;263(1):238-45
10429209
J Virol. 2002 Feb;76(4):1753-61
11799170
Virology. 2008 Sep 1;378(2):272-81
18599104
J Virol. 1997 Aug;71(8):5723-32
9223458
J Clin Virol. 2008 Aug;42(4):405-8
18472298
Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5597-601
8202533
PLoS Med. 2007 Jan;4(1):e36
17227139
Antimicrob Agents Chemother. 2004 Feb;48(2):437-43
14742192
Structure. 2002 Mar;10(3):369-81
12005435
Ann Pharmacother. 1999 Mar;33(3):325-39
10200859
AIDS. 2007 May 31;21(9):1210-3
17502734
J Virol. 2002 Aug;76(15):7398-406
12097552
Antimicrob Agents Chemother. 2005 Sep;49(9):3825-32
16127059
J Virol. 1997 Sep;71(9):6662-70
9261388
AIDS Res Hum Retroviruses. 2000 Sep 1;16(13):1209-13
10957718
J Virol. 2006 Apr;80(7):3607-16
16537628
Antimicrob Agents Chemother. 1998 Oct;42(10):2637-44
9756769
Antimicrob Agents Chemother. 1998 Nov;42(11):2775-83
9797203
J Virol. 1997 Feb;71(2):1089-96
8995629
Antimicrob Agents Chemother. 2000 Apr;44(4):920-8
10722492
J Virol. 2004 Nov;78(22):12446-54
15507631
Biochemistry. 1995 Jul 25;34(29):9282-7
7626598
AIDS. 1999 Dec 3;13(17):2349-59
10597776
Chem Biol. 2004 Oct;11(10):1333-8
15489160
J Infect Dis. 2004 May 15;189(10):1802-10
15122516
Adv Exp Med Biol. 1998;436:75-83
9561202
Virology. 2006 Apr 10;347(2):405-9
16430939
Antimicrob Agents Chemother. 2002 Apr;46(4):1086-92
11897594
PLoS Pathog. 2009 Mar;5(3):e1000345
19300491
AIDS Res Hum Retroviruses. 2006 Dec;22(12):1300-5
17209774
J Virol. 1996 Jun;70(6):3763-9
8648711
Nucleic Acids Res. 2003 Jan 1;31(1):298-303
12520007
Antiviral Res. 1998 Jul;39(1):1-23
9754946